RGRuben Iglesias Gomez

Ruben Iglesias Gomez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruben Iglesias Gomez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Conxa Borrás Almenar

    Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    1 shared publication
  • Eduardo López-Briz

    Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    1 shared publication
  • Isabel Font Noguera

    Pharmacy department Hospital Universitari i Politècnic La Fe Avinguda de Fernando Abril Martorell, Valencia Spain

    1 shared publication
  • Isabel Font-Noguera

    Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    1 shared publication
  • Jose Luis Poveda Andres

    Pharmacy department Hospital Universitari i Politècnic La Fe Avinguda de Fernando Abril Martorell, Valencia Spain

    1 shared publication
  • José Andrés Román Iborra

    Rheumatology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    1 shared publication

Latest Publications

  • Tall man lettering application in medication information systems as a quality and safety strategy in hospital organization

    by Ruben Iglesias Gomez, Isabel Font Noguera, Marta Correa Ballester, Maria Jose Ruiz Caldes, Jose Luis Poveda Andres

    The technique of highlighted capital letters, Tall Man lettering, is a tool that allows differentiating the names of similar drugs in a way that contributes to reduce medication errors related to the drug identification. The objective was to implement and monitor the application protocol of the Tall Man lettering tool in drug information systems in the healthcare environment to improve the quality of care and patient safety in the pharmacy service and the medical institution. Scope: Tertiary general hospital with 1000 beds in which a Tall Man lettering application protocol was approved in the pharmacy service information systems. Retrospective observational study. 2019-2021. Information systems and databases used in the pharmacy service. Working group: Made up of people in charge of information areas and systems. Five phases were defined: organization of the working group, selection of drug names and information systems, establishment of actions, their execution, and results monitoring. Number of pharmaceutical specialties, names of active ingredient and brands incorporated in the information systems. The application of Tall Man lettering was authorized in 13/13 information systems, six have been fully implemented and seven are in the database update phase. Of the implanted systems, a total of 210 drug names have been modified (168/210 active ingredient and 42/210 brand names), corresponding to 659 pharmaceutical specialties. The application of Tall Man lettering in hospital information systems is a tool for improving the quality of the pharmacy service and guarantees the safety of medicines in the hospital.


  • Open Access

    Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients

    by Rubén Iglesias Gómez, Raúl Méndez, Tomás Palanques-Pastor, Octavio Ballesta-López, Conxa Borrás Almenar, Juan Eduardo Megías Vericat, Eduardo López-Briz, Isabel Font-Noguera, Rosario Menéndez Villanueva, José Andrés Román Iborra, et al.

    Objectives To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis. Methods This was an observational retrospective study of hospitalised patients treated with baricitinib for severe COVID-19. Outcomes were clinical improvement on an ordinal scale of 1–8 on day 1 of baricitinib compared with day 14 (where 8=death and 1=not hospitalised with no limitations of activities), overall survival, time to recovery since baricitinib treatment started (days until hospital discharge) and laboratory parameters related to COVID-19 poor prognosis. Adverse events related to baricitinib during the admission period were also reported. Results Forty-three patients (70% men, mean age 70 years (IQR 54–79)) treated with baricitinib daily for 6 days (IQR 5–7) were included. Thirty-six patients were treated with corticosteroids (84%). Clinical improvement was 3 points (IQR 1–4) in patients on an ordinal scale of 4–6, overall survival was 100% at day 30 and day 60 with a mean time to recovery of 12 days (IQR 9–25) from start of baricitinib treatment. No adverse events of interest were found and all poor prognosis risk factors improved at day 14: interleukin-6, C-reactive protein, ferritin, lymphocytes, platelets and D-dimers. Conclusions Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib.